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ABSTRACT: Genetically determined myoclonus disor-
ders are a result of a large number of genes. They have
wide clinical variation and no systematic nomenclature.
With next-generation sequencing, genetic diagnostics
require stringent criteria to associate genes and phenotype.
To improve (future) classiﬁcation and recognition of geneti-
cally determined movement disorders, the Movement Dis-
order Society Task Force for Nomenclature of Genetic
Movement Disorders (2012) advocates and renews the
naming system of locus symbols. Here, we propose a
nomenclature for myoclonus syndromes and related disor-
ders with myoclonic jerks (hyperekplexia and myoclonic
epileptic encephalopathies) to guide clinicians in their diag-
nostic approach to patients with these disorders. Sixty-
seven genes were included in the nomenclature. They were
divided into 3 subgroups: prominent myoclonus syn-
dromes, 35 genes; prominent myoclonus syndromes com-
bined with another prominent movement disorder, 9 genes;
disorders that present usually with other phenotypes but
can manifest as a prominent myoclonus syndrome,
23 genes. An additional movement disorder is seen in
nearly all myoclonus syndromes: ataxia (n = 41), ataxia and
dystonia (n = 6), and dystonia (n = 5). However, no addi-
tional movement disorders were seen in related disorders.
Cognitive decline and epilepsy are present in the vast
majority. The anatomical origin of myoclonus is known in
64% of genetic disorders: cortical (n = 34), noncortical
areas (n = 8), and both (n = 1). Cortical myoclonus is com-
monly seen in association with ataxia, and noncortical
myoclonus is often seen with myoclonus-dystonia. This
new nomenclature of myoclonus will guide diagnostic test-
ing and phenotype classiﬁcation. © 2019 The Authors.
Movement Disorders published by Wiley Periodicals, Inc.
on behalf of International Parkinson and Movement Disor-
der Society.
Key Words: genetics; hyperekplexia; myoclonic
epilepsy; myoclonus; nomenclature
Myoclonus is a hyperkinetic movement disorder char-
acterized by sudden, brief, involuntary jerks of a single
or multiple muscles.1-3 It can be caused by muscle
contraction (positive myoclonus) or sudden interruption
of muscle activity during intended isometric contraction
(negative myoclonus).4 The myoclonic jerks can be difﬁcult
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to distinguish from other hyperkinetic movement disor-
ders.5 Electrophysiological testing has proven helpful for
discriminating myoclonus from other hyperkinetic move-
ment disorders and for classifying the myoclonus subtype.6
Myoclonus can be classiﬁed based on anatomical origin:
cortical, subcortical (or noncortical7), spinal, and periph-
eral myoclonus.6 So far, in genetic myoclonus syndromes
only cortical (CM) and subcortical subtypes have been
described.8
Determination of the etiology of myoclonus is challeng-
ing, and recently, a novel diagnostic 8-step algorithm was
proposed to help clinicians accurately, efﬁciently, and
cost-effectively diagnose myoclonus.8 Once the acquired
forms and late-onset neurodegenerative disorders (such as
Alzheimer’s disease and parkinsonian disorders) of myoc-
lonus are excluded in this diagnostic workup, a large
number of genetically determined disorders with wide
clinical variation remain. In almost all genetic syndromes,
myoclonus is not the sole feature, but it is accompanied
or even overshadowed by another movement disorder.5
This is likely the reason systematic nomenclature similar
to PARK (for parkinsonism) or DYT (for dystonia) has
not been established for myoclonus. In many of the
suspected genetic myoclonus syndromes, the genetic cause
is (still) unknown, but next-generation sequencing (NGS)
has revolutionized molecular genetic diagnosis and has
produced an exponential increase in known genetic causes
and expansion of movement disorder phenotypes, includ-
ing myoclonus. However, NGS frequently produces
genetic variants for which pathogenicity is unclear. This
emphasizes the importance of good clinical phenotyping
and weighting of NGS results in the context of the pre-
senting clinical syndrome.
In 2012, the International Parkinson and Movement
Disorder Society Task Force for Nomenclature of Genetic
Movement Disorders was established to revise the system
of locus symbols, as the current movement disorders sys-
tem had become outdated with the advances in NGS, the
lack of established criteria for conferring locus symbols,
or ongoing revision of the list.9
Here we present a new myoclonus nomenclature. We
also include groups of related disorders that can present
in the outpatient clinic of a movement disorder special-
ist with jerks as a prominent symptom. First, there are
the hyperekplexias, as the excessive startle reﬂex closely
resembles reticular reﬂex myoclonus, both clinically
and neurophysiologically.10 Second are the genetic epilepsy
syndromes with myoclonic jerks, speciﬁcally the epileptic
encephalopathies. Patients with myoclonic epilepsy enceph-
alopathies exhibit, next to their clear epileptic attacks, often
spontaneous, reﬂex or action myoclonus, with evidence of a
cortical origin. These cortically driven epileptic jerks resem-
ble isolated cortical myoclonus, as both are characterized by
short-lasting (<100-millisecond) jerks with a cortical dis-
charge on the electroencephalogram (EEG). Historically, it
is not clear if there is a neurobiological distinction between
the 2 phenomena, and therefore we decided to include them
both in the currentmyoclonus nomenclature.
The ﬁrst 2 papers of the task force included the pro-
posed nomenclature for genetic parkinsonism, dysto-
nia, autosomal-dominant and -recessive cerebellar
ataxia, hereditary spastic paraplegia, paroxysmal move-
ment disorders, neurodegeneration with brain iron
accumulation, and primary familial brain calciﬁca-
tion.1,2 Here, we present the genetically determined
myoclonus syndromes nomenclature based on the same
principles, criteria, and recommendations.
Methods
Inclusion
Our recommendations are based on a systematic liter-
ature search. All articles regarding genetic causes of
myoclonus syndromes were identiﬁed by a PubMed,
Online Mendelian Inheritance in Man, and Textbook
search, including all the additional relevant references cited
in the articles found. The key search terms “myoclonus,”
“myoclonic epilepsy,” and “startle” were used in combi-
nation with the term “genetic causes.” For the period to
June 2015, we used our previously published systematic
review with the same search terms.8 In addition, an identi-
cal search was performed for the period between June
2015 and October 2018 to identify newly discovered
genes. All reviewed articles and abstracts were restricted to
those published in English.
Following the recommendations of the task force, the
criteria for gene inclusion are that mutations in the gene
must be causative (ie, risk factor genes were excluded),
and myoclonus must be a prominent feature. In deter-
mining the pathogenicity, no speciﬁc threshold for the
level of penetrance of a mutation was designated by the
Movement Disorder Society (MDS) Task Force and
was determined for each gene based on standards prev-
ailing in the ﬁeld. In the ﬁeld of myoclonus, we decided
that genes related to myoclonus or myoclonic epilepsy
with medium or low penetrance were excluded. In
Table 1 we included genetic disorders DYT-ANO3 and
CHOR-NKX2-1, although the penetrance of these
genes is reduced. The reason to include them is that the
previous nomenclature of the MDS Task Force decided
to include lower penetrance, as it is more common in
dystonic syndromes and these 2 genes present with the
clinical syndrome of myoclonus-dystonia.
Prominent myoclonus was present if either (1) the lit-
erature stated that myoclonic jerks were a prominent
feature of the phenotype, (2) the myoclonic jerks were
the main reason for disability, and/or (3) the myoclonic
jerks were the main focus of treatment. In addition to
this, the predominance of myoclonus in the disorder
had to be conﬁrmed in the literature by a second inde-
pendent group of researchers.1
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This adjudication process included 2 persons (S.V.
and R.Z.). All genes included in the new nomenclature
were reviewed by 6 experts within the ﬁeld of myoclo-
nus to reach a broadly supported consensus (H.S., J.C.,
S.B., P.T., T.K., M.T.).
Classiﬁcation
Following the recommendation of the task force and
to guide clinicians in daily practice, the genetic disor-
ders were allocated based on clinical presentation into
1 of the following 3 groups: (1) prominent myoclonus
syndromes, genetic disorders that present with promi-
nent myoclonus in the majority of cases; (2) combined
myoclonus syndromes, genetic disorders that present
with prominent myoclonus and another prominent
movement disorder (eg, dystonia/ataxia) in the majority
of cases; and (3) disorders that usually present with
other phenotypes but can manifest as a prominent
myoclonus syndrome, genetic disorders that present
with prominent myoclonus only in a minority of cases
as part of the phenotypic spectrum of this disorder.
Preﬁxes
In accordance with the recommendations of the task
force, the preﬁx MYC was given to genes in which
myoclonus is a prominent feature in the majority of the
patients. In addition, we added a second preﬁx to genes
and consequently allocated it to the subgroup combined
myoclonus syndromes, in which another movement dis-
order is an additional prominent feature, resulting in a
double preﬁx if both movement disorders are promi-
nent (eg, MYC/ATX-GOSR2). Overlapping genes with
double preﬁxes were discussed among the appropriate
experts from the MDS Task Force to reach consensus.
The symbol preﬁx is followed by the gene name. For
clarity and to allow comparison with former classiﬁca-
tions, we provided the old locus symbol (eg, DYT11) in
the last column of Table 1, when appropriate. Genes
that present with myoclonic epilepsy were not given
any preﬁx, because the dominant feature of the pheno-
type is epilepsy rather than a movement disorder.
Additional Clinical and Electrophysiological
Items
A brief description of the clinical presentation of disor-
ders linked to each gene is listed in Table 1 with special
emphasis on the most common accompanying signs and
symptoms including ataxia, dystonia, cognitive prob-
lems, or epilepsy. Furthermore, we added the myoclonic
anatomical subtype, cortical or subcortical (ie, non-
cortical), if known, for each genetic disorder based on
reported clinical and electrophysiological features to fur-
ther improve the classiﬁcation of myoclonus. Experts
have argued against the term “subcortical” myoclonus,
as its anatomical origin is still undetermined; however,
the term “subcortical” myoclonus will still be used in the
new nomenclature because of the absence of a widely
supported alternative.7 See Supplementary Table 1 for
the anatomical classiﬁcation criteria for myoclonus.93
Results
Gene Selection
One hundred sixty-six genes linked to a myoclonus
syndrome were found in the systematic literature review.
An extensive overview of all genes associated with myoc-
lonus with reason for inclusion or exclusion can be
found in Supplementary Table 3, and see Figure 1 for an
overview. Nighty-nine genes were excluded because of
the absence of prominent myoclonus (n = 45), lack of
conﬁrmation of the phenotype with prominent myoclo-
nus by a second independent research group (n = 31),
and questionable pathogenicity (n = 23).
Sixty-seven genes were included in the new nomencla-
ture for myoclonus syndromes (see Table 1). (1) In the
subgroup prominent myoclonus syndromes, 35 genes
were included; (2) in the subgroup combined myoclonus
syndromes, 9 genes were included; and (3) in the sub-
group disorders that usually present with other pheno-
types but can manifest as a prominent myoclonus
syndrome, 23 genes were included.
Preﬁx Allocation
The locus symbol preﬁx MYC was assigned to
22 genes. Genes in which the predominant phenotype
showed wide heterogeneity or was dominated by epi-
leptic or nonmotor symptoms were not assigned any
preﬁx. For myoclonus epilepsy with ragged red ﬁbers
syndrome, only the most frequent causative gene (mt-
MTTK) is listed. The remaining causative genes are
stated in the caption of Table 1, as they are associated
with a similar phenotype as mt-MTTK.
FIG. 1. In and exclusion of genes associated with myoclonus syndromes.
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Additional Clinical and Electrophysiological
Clues
The following most common accompanying signs and
symptoms observed overall were cognitive decline in 90%
(n = 60), epilepsy in 82% (n = 55), ataxia in 61% (n = 41),
ataxia and dystonia in 9% (n = 6), and dystonia in 7%
(n = 5). The anatomical location of myoclonic origin could
be allocated in 64% of genes (n = 43) because of support
of strong electrophysiological data, and in the cortex in
51% (n = 34), noncortical areas in 12% (n = 8), and both
cortical and noncortical areas in 1% (n = 1) of all genes.
Three of the 8 genes with jerks originating from non-
cortical areas were classiﬁed as originating from the brain
stem (hyperekplexia).
Discussion
In this article we propose a nomenclature of geneti-
cally determined myoclonus according to the new nam-
ing system presented by the MDS Task Force.1 This
myoclonus list currently includes 67 genes. Thirty-ﬁve
genes presented with prominent myoclonus syndromes,
9 with combined myoclonus syndromes, and 23 with
disorders that usually present with other phenotypes but
can manifest as a prominent myoclonus syndrome. Co-
occurrence of movement disorders, especially ataxia and
dystonia, was seen in almost all except for familial corti-
cal myoclonus tremor with epilepsy (FCMTE, or
BAFME, benign adult familial myoclonus epilepsy),
hyperekplexia, and (myoclonic) epileptic encephalopa-
thies. Epilepsy and cognitive decline were the most fre-
quently observed accompanying clinical features for the
disorders listed in this new nomenclature.
The literature search detected 166 genes linked to a
myoclonus syndrome, but only 67 were used for the
nomenclature list. Filtering using strict criteria (indepen-
dent conﬁrmation and predominant myoclonus) to arrive
at a list of conﬁrmed entities that can present with predomi-
nant myoclonus is meant to help the clinician with the
selection of test procedures and assist in the interpretation
of results of genetic testing.2 In our opinion, the require-
ment for independent conﬁrmation by a second research
group is an important criterion, as it diminishes erroneous
genotype-phenotype linkages. At present, with the wide-
spread use of NGS in research and clinical diagnostics,
many potentially new myoclonus genes are reported. Still,
we had to exclude 31 genes (19%) that require validation.
A signiﬁcant proportion of patients with myoclonus syn-
dromes still remain unsolved (progressive myoclonus
ataxias in 36%94 and progressive myoclonus epilepsies in
28%95), in which excluded genes could be considered.
A new clinical diagnostic approach in patients with
myoclonus has recently been described.8 After establishing
that the myoclonus in a patient has a genetic cause,
Table 1 can be used as a diagnostic framework for
physicians in clinical practice to select candidate genes for
individual patients based on the absence or presence of
accompanying signs and symptoms.
FCMTE/BAFME is the only genetically determined
myoclonus syndrome with relatively pure myoclonus,
although it is accompanied by infrequent epilepsy in a
majority of but not all patients. This genetic disorder is
caused by 2 recently conﬁrmed genes (MYC-SAMD12
and MYC-RAPGEF2) with intronic expansions of non-
coding TTTCA and TTTTA pentanucleotide repeats. It
presents with a phenotype of benign CM with infre-
quent tonic-clonic and sometimes focal seizures. RNA-
mediated toxicity resulting in diffuse loss of Purkinje
cells in the cerebellum is suggested to be the underlying
pathogenesis of this disorder.96,97 The potential role of
the cerebellum in CM has been pointed out multiple
times in the literature, supported by the frequent pheno-
typical co-occurrence of CM and cerebellar ataxia.98
Ataxia is the most common accompanying movement
disorder in myoclonus syndromes (24 genes). Almost
all patients in whom the genetic disorder consists of a
combination of ataxia and myoclonus present with the
clinical syndrome of progressive myoclonus ataxia
(PMA) or progressive myoclonus epilepsy (PME). The
most common and best characterized are Unverricht-
Lundborg disease (MYC/ATX-CSTB), Lafora disease
(MYC/ATX-EMP2A), neuronal ceroid lipofuscinosis
(multiple genes), sialidosis (MYC/ATX-NEU`1), and
dentatorubral pallidoluysian atrophy (ATX-ATN1).99
The anatomical origin ofmyoclonus inmost patients with
ataxia is thought to be cortical. Clinically, cortical myo-
clonic jerks present typically in the distal limbs and face,
jerks are provoked by action and are stimulus sensitive.93Of
the genetic disorders in which ataxia and myoclonus co-
occur,we found that cortical originwas supported by strong
electrophysiological evidence in 54% (n = 14), and it was
suspected in 33% (n = 8). Mechanistic hypotheses for corti-
cal myoclonus include: (1) loss of Purkinje cells with
astrocytosis, resulting in disinhibition via the cerebello-
thalamico-cortical pathway, (2) neuronal cell loss in the den-
tate nuclei leading to impaired cerebellar projections to
the cortex, or (3) a reduction in the concentration of
γ-aminobutyric acid (GABA)-ergic synapses in the sensory-
motor cortex.100 On a molecular level, most genetic disor-
ders presenting with both ataxia and myoclonus have
impaired posttranslational modiﬁcation of proteins to
which certain neuronal groups might be particularly vulner-
able compared with others.100 This could play a role in the
characteristic phenotype of PMA, including a ﬁxed order of
signs, startingwith ataxia, subsequently CM, and eventually
by infrequent epilepsy.94
Dystonia is the second type of prominent movement dis-
order accompanying myoclonus. The combination of
myoclonus and dystonia is known as myoclonus-dystonia
syndrome (M-D). The classical myoclonus-dystonia phe-
notype is based on genetic defects in the MYC/DYT-
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SGCE gene in about 50% of cases.101 Other disorders that
can give rise to a myoclonus-dystonia phenotype in-
clude MYC/DYT-KCTD17, DYT-ANO3, ATX-PRKCG,
ATX-ATM, CHOR/DYT-ADCY5, CHOR-NKX2-1, and
maternal uniparental disomy with regions of heterodisomy
and isodysomy on chromosome 7 (mUPD7), which is
based on the loss of function of the SGCE gene.
The anatomical locus of myoclonus in M-D is subcor-
tical. Clinically, the myoclonus and dystonia in M-D
are located mainly in the trunk and proximal upper
limbs, and the myoclonus is not stimulus sensitive. The
noncortical origin of the myoclonus is supported elec-
trophysiologically in 5 genetic disorders presenting with
M-D (MYC/DYT-SGCE, MYC/DYT-KCTD17, DYT-
ANO3, ATX-ATM, ATX-PRKCG) and unknown in
2 others (CHOR/DYT-ADCY5 and CHOR-NKX2-1).
The pathophysiology of subcortical myoclonus includes
circuit abnormalities in the basal ganglia and involve-
ment of the cerebellum. Disruptions in neurotransmis-
sion pathways have been hypothesized to play a role,
particularly the unbalanced homeostasis of GABA,
serotonin, and dopamine-related pathways.102 In con-
trast to myoclonus of cortical origin, cortical excitabil-
ity and intracortical inhibition were found to be normal
or less profoundly disturbed.103
The overlap between types of accompanying move-
ment disorders and the anatomical origins of the myo-
clonic jerks is remarkable. Currently, the anatomical
origin can be assigned in only 64% of genetic disorders.
We encourage movement disorder specialists to classify
the subtype of myoclonus by a thorough clinical descrip-
tion (eg, distribution, stimulus sensitivity) of the myo-
clonic jerks and if possible electrophysiological testing
(eg, corticomuscular coherence or jerk-locked back-aver-
aging). We realize that availability of the tests varies con-
siderably between centers and countries.6 However, the
myoclonic subtype guides the clinician toward a more
precise differential diagnosis (see Table 1) and effective
treatment strategy,104 and it helps to unravel the patho-
genesis of myoclonus by creating homogenous groups.
Epilepsy is an additional feature in 82% of myoclonus
syndromes, presenting either as CM in combination with
epilepsy or myoclonic jerks as part of a myoclonic seizure.
It is only described in genes with jerks originating from the
cortex, as mutations in genes linked to noncortical myoc-
lonus (hyperekplexia, all M-D syndromes, and Cofﬁn-
Lowry syndrome) rarely present with epileptic manifesta-
tions. The distinction betweenmyoclonus and (myoclonic)
epilepsy can be difﬁcult to make, and seemingly minor dif-
ferences in terminology can create confusion. Myoclonus
epilepsy is a condition in which CM, often continuously
present, and epilepsy occur independently, whereas myo-
clonic epilepsy is an attack of generalized convulsions
starting with myoclonic jerks or predominantly character-
ized by myoclonic jerks. Jerks in both CM and myoclonic
epilepsy are associated with EEG polyspikes or spike/
polyspike-wave complexes before the onset of an EMG
burst.105 Confusion is not only the case in clinical practice
but also in the literature, making it difﬁcult to interpret
many of the clinical presentations described. For instance,
the phenotype associated with MYC/ATX-GOSR2 has
been called an epileptic syndrome with myoclonic seizures
(progressive myoclonus epilepsy type 6) in articles from
the ﬁeld of epilepsy,106 as opposed to a syndrome with
prominent cortical myoclonus in combination with epi-
lepsy (progressive myoclonus ataxia) in articles from the
ﬁeld of movement disorders.107 Particularly in the ﬁelds of
movement disorders and epilepsy, the phenotype is a deci-
sive factor for further diagnostics, and inaccuracy of
descriptions can lead to erroneous genotype-phenotype
relationships. Ongoing discussion and consensus meetings
between experts in both ﬁelds are necessary to accomplish
a consistent terminology with clear deﬁnitions that could
easily be implemented in clinical practice.
Cognitive problems including cognitive decline and
psychomotor retardation have been reported in all but
5 genetic disorders, MYC/DYT-SGCE, MYC/DYT-
KCTD17, mUDP7 (based on loss of SGCE-gene),
DYT-ANO3, and the hyperekplexias. Other nonmotor
features, particularly psychiatric disorders and behav-
ioral problems, are also being recognized as part of the
phenotype of certain movement disorders (eg, dystonia).
In disorders with cortical myoclonus, almost half the
patients experience symptoms of depression or anxi-
ety.108 Underestimation of these nonmotor features is
likely, as we have only recently started considering this
to be part of the phenotype. Future case descriptions of
myoclonus syndromes should include details on cogni-
tion, psychiatric symptoms, and behavioral changes. The
clinician should be aware of the high occurrence of non-
motor features in patients with myoclonus syndromes.
These are features that impact the patient’s life and his
or her family, and they require proper guidance and
counseling.109
Just as the presence of accompanying signs and symp-
toms can guide clinicians to a reﬁned differential diagno-
sis, absence of an accompanying movement disorder
proves a useful observation, as it points toward the
related disorders, hyperekplexia and myoclonic epileptic
encephalopathies. Hyperekplexia is characterized by
3 clinical symptoms: generalized stiffness at birth, exces-
sive startle reﬂexes, and generalized stiffness following a
startle. Genetic studies have shown mutations in different
parts of the inhibitory glycine receptor complex, located
in the postsynaptic membrane of glycinergic and mixed
GABAergic neurons. Synaptic inhibition in the brain stem
and spinal cord is impaired as a result of a defect in 1 of
these 3 genes.10 With regard to the genes identiﬁed in epi-
leptic encephalopathies with prominent myoclonic jerks,
a majority of these disorders share a phenotype that
includes early disease onset (in the ﬁrst 18 months of life)
and a progressive course resulting in refractory epilepsy
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and severe cognitive decline. However, some genetic dis-
orders are extremely rare (eg, CARS2), and those pheno-
types are likely to be expanded in the coming years.
Conclusion
In collaboration with the MDS Task Force, we present
a new nomenclature that includes 67 genetically deter-
mined myoclonus syndromes. As is apparent from this
current list, numerous genes are linked to myoclonus
syndromes, and prioritizing putative causative genes
based on corresponding accompanying signs or symp-
toms and clinical clues could accelerate the identiﬁcation
of a molecular diagnosis in individual cases. Further-
more, it shows the additional value of electrophysiologi-
cal testing in patients with myoclonus syndromes, as it
may lead to a more reﬁned differential diagnosis and
therapeutic strategy. The current nomenclature can be
used as a framework to add newly discovered genes in a
systematic way and can be used for movement disorder
(myoclonus) next-generation sequencing diagnostics. In
the near future, genetically determined myoclonus syn-
dromes can be uploaded in the searchable online data-
base, the Movement Disorder Society Genetic Mutation
Database, MDSGene (www.MDSGene.org), to provide
an online, browsable database of hereditary myoclonus
syndromes.110
Acknowledgments: The authors are grateful to P.D. Thompson of the
University of Adelaide and Royal Adelaide Hospital in Adelaide,
Australia, for his critical review of the manuscript and helpful comments.
The authors also thank the International Parkinson and Movement Disor-
der Society for supporting the Task Force on Nomenclature and Classiﬁ-
cation of Inherited Movement Disorders.
References
1. Marras C, Lang A, van de Warrenburg BP, et al. Nomenclature of
genetic movement disorders: Recommendations of the international
Parkinson and movement disorder society task force. Mov Disord
2016;31:436–457.
2. Rossi M, Anheim M, Durr A, et al. The genetic nomenclature of
recessive cerebellar ataxias. Mov Disord 2018;33:1056–1076.
3. Caviness JN. Myoclonus. Mayo Clin Proc 1996;71:679–688.
4. Shibasaki H, Hallet M. The Neurological Examination: Scientiﬁc
Basis for Clinical Diagnosis. New York: Oxford University Press;
2016.
5. Van Egmond ME, Elting JWJ, Kuiper A, et al. Myoclonus in
childhood-onset neurogenetic disorders: The importance of early
identiﬁcation and treatment. Eur J Paediatr Neurol 2015;19:
726–729.
6. Zutt R, Elting JW, van Zijl JC, et al. Electrophysiologic testing aids
diagnosis and subtyping of myoclonus. Neurology 2018;90:
e647–e657.
7. Shibasaki H, Thompson PD. Milestones in myoclonus. Mov Disord
2011;26:1142–1148.
8. Zutt R, van Egmond ME, Elting JW, et al. A novel diagnostic
approach to patients with myoclonus. Nat Rev Neurol 2015;11:
687–697.
9. Marras C, Lohmann K, Lang A, Klein C. Fixing the broken system
of genetic locus symbols: Parkinson disease and dystonia as exam-
ples. Neurology 2012;78:1016–1024.
10. Dreissen YEM, Tijssen MAJ. The startle syndromes: Physiology
and treatment. Epilepsia 2012;53:3–11.
11. Munroe PB, Mitchison HM, O’Rawe AM, et al. Spectrum of muta-
tions in the Batten disease gene, CLN3. Am J Hum Genet 1997;61:
310–316.
12. Peltonen L, Savukoski M, Klockars T, Holmberg V, Santavuori P,
Lander ES. CLN5, a novel gene encoding a putative transmem-
brane protein mutatedin Finnish variant late infantile neuronal
ceroid lipofuscinosis. Nat Genet 1998;19:286–288.
13. Gao H, Boustany R-MN, Espinola JA, et al. Mutations in a novel
CLN6-encoded transmembrane protein cause variant neuronal ceroid
lipofuscinosis in man and mouse. Am J Hum Genet 2002;70:324–335.
14. Arsov T, Smith KR, Damiano J, et al. Kufs Disease, the Major
Adult Form of Neuronal Ceroid Lipofuscinosis, Caused by Muta-
tions in CLN6. Am J Hum Genet 2011;88:566–573.
15. Ranta S, Zhang Y, Ross B, et al. The neuronal ceroid
lipofuscinoses in human EPMR and mnd mutant mice are associ-
ated with mutations in CLN8. Nat Genet 1999;23:233–236.
16. Cadieux-Dion M, Andermann E, Lachance-Touchette P, et al.
Recurrent mutations in DNAJC5 cause autosomal dominant Kufs
disease. Clin Genet 2013;83:571–575.
17. Shiang R, Ryan SG, Zhu Y-Z, Hahn AF, O’Connell P,
Wasmuth JJ. Mutations in the alpha-1 subunit of the inhibitory
glycine receptor cause the dominant neurologic disorder, hyper-
ekplexia. Nat Genet 1993;5:351–357.
18. Rees MI, Harvey K, Pearce BR, et al. Mutations in the gene
encoding GlyT2 (SLC6A5) deﬁne a presynaptic component of
human startle disease. Nat Genet 2006;38:801–806.
19. Rees MI, Lewis TM, Kwok JBJ, et al. Hyperekplexia associated
with compound heterozygote mutations in the beta-subunit of the
human inhibitory glycine receptor (GLRB). Hum Mol Genet 2002;
11:853–860.
20. Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo
mutation in KCNC1 causes progressive myoclonus epilepsy. Nat
Genet 2015;47:39–46.
21. Bassuk AG, Wallace RH, Buhr A, et al. A Homozygous Mutation
in Human PRICKLE1 Causes an Autosomal-Recessive Progressive
Myoclonus Epilepsy-Ataxia Syndrome. Am J Hum Genet 2008;83:
572–581.
22. Ishiura H, Doi K, Mitsui J, et al. Expansions of intronic TTTCA
and TTTTA repeats in benign adult familial myoclonic epilepsy.
Nat Genet 2018;50:581–590.
23. Lei XX, Liu Q, Lu Q, et al. TTTCA repeat expansion causes famil-
ial cortical myoclonic tremor with epilepsy. Eur J Neurol 2018:
26(3):513–518.
24. Berkovic SF, Dibbens LM, Oshlack A, et al. Array-Based Gene Dis-
covery with Three Unrelated Subjects Shows SCARB2/LIMP-2
Deﬁciency Causes Myoclonus Epilepsy and Glomerulosclerosis.
Am J Hum Genet 2008;82(3):673–684.
25. Steinfeld R, Grapp M, Kraetzner R, et al. Folate Receptor Alpha
Defect Causes Cerebral Folate Transport Deﬁciency: A Treatable
Neurodegenerative Disorder Associated with Disturbed Myelin
Metabolism. Am J Hum Genet 2009;85:354–363.
26. Ortigoza Escobar JD, Pérez Dueñas B. Treatable Inborn Errors of
Metabolism Due to Membrane Vitamin Transporters Deﬁciency.
Semin Pediatr Neurol 2016;23:341–350.
27. Hallmann K, Zsurka G, Moskau-Hartmann S, et al. A homozy-
gous splice-site mutation in CARS2 is associated with progressive
myoclonic epilepsy. Neurology 2014;83:2183–2187.
28. Coughlin CR, Scharer GH, Friederich MW, et al. Mutations in the
mitochondrial cysteinyl-tRNA synthase gene, CARS2, lead to a
severe epileptic encephalopathy and complex movement disorder.
J Med Genet 2015;52:532–540.
29. Carvill GL, Heavin SB, Yendle SC, et al. Targeted resequencing in
epileptic encephalopathies identiﬁes de novo mutations in CHD2
and SYNGAP1. Nat Genet 2013;45:825–830.
30. Thomas RH, Zhang LM, Carvill GL, et al. CHD2 myoclonic
encephalopathy is frequently associated with self-induced seizures.
Neurology 2015;84:951–958.
10 Movement Disorders, 2019
V A N D E R V E E N E T A L
31. Chatron N, Møller RS, Champaigne NL, et al. The epilepsy pheno-
typic spectrum associated with a recurrent CUX2 variant. Ann
Neurol 2018;83:926–934.
32. Tada K, Kure S, Kume A, Hiraga K. Genomic Analysis of Non-
ketotic Hyperglycinaemia: A Partial Deletion of P-protein Gene.
J lnher Metab Dis 1990;13(5):766–770.
33. Nanao K, Takada G, Takahashi E-I, et al. Structure and Chromo-
somal Localization of the Aminomethyltransferase Gene (AMT).
Genomics 1994;19:27–30.
34. Shoffner JM, Lott MT, Lezza a M, Seibel P, Ballinger SW,
Wallace DC. Myoclonic epilepsy and ragged-red ﬁber disease
(MERRF) is associated with a mitochondrial DNA tRNA(Lys)
mutation. Cell 1990;61:931–937.
35. Tranchant C, Anheim M. Movement disorders in mitochondrial
diseases. Rev Neurol 2016;172:524–529.
36. Johnston JJ, GropmanAL, Sapp JC, et al. The Phenotype of a Germline
Mutation in PIGA: TheGene SomaticallyMutated in ParoxysmalNoc-
turnal Hemoglobinuria. Am JHumGenet 2012;90:295–300.
37. Van Goethem G, Dermaut B, Löfgren A, Martin J-J, Van
Broeckhoven C. Mutation of POLG is associated with progressive
external ophthalmoplegia characterized by mtDNA deletions. Nat
Genet 2001;28:211–212.
38. Claes L, Del-Favero J, Ceulemans B, Lagae L, Broeckhoven C Van,
De Jonghe P. De Novo Mutations in the Sodium-Channel Gene
SCN1A Cause Severe Myoclonic Epilepsy of Infancy. Am J Hum
Genet 2001;68:1327–1332.
39. Davis RL, Shrimpton a E, Holohan PD, et al. Familial dementia caused
by polymerization of mutant neuroserpin. Nature 1999;401:376–379.
40. Davis RL, Shrimpton AE, Carrell RW, et al. Association between
conformational mutations in neuroserpin and onset and severity of
dementia. Lancet 2002;359:2242–2247.
41. Carvill GL, McMahon JM, Schneider A, et al. Mutations in the
GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-
Atonic Seizures. Am J Hum Genet 2015;96:808–815.
42. Falace A, Filipello F, La Padula V, et al. TBC1D24, an
ARF6-Interacting Protein, Is Mutated in Familial Infantile Myo-
clonic Epilepsy. Am J Hum Genet 2010;87:365–370.
43. Balestrini S, Milh M, Castiglioni C, et al. TBC1D24 genotype –
phenotype correlation Epilepsies and other neurologic features.
Neurology 2016:77–87.
44. Pennacchio LA, Lehesjoki AE, Stone NE, et al. Mutations in the
gene encoding cystatin B in progressive myoclonus epilepsy
(EPM1). Science 1996;271:1731–1734.
45. Crespel A, Ferlazzo E, Franceschetti S, et al. Unverricht-Lundborg
disease. Epileptic Disord 2016;18:28–37.
46. Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene
encoding a novel protein tyrosine phosphatase cause progressive
myoclonus epilepsy. Nat Genet 1998;20:171–174.
47. Turnbull J, Tiberia E, Striano P, et al. Lafora disease. Epileptic Dis-
ord 2016;18:S38–S62.
48. Corbett MA, Schwake M, Bahlo M, et al. A mutation in the Golgi
Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy
with early ataxia. Am J Hum Genet 2011;88:657–663.
49. Van Bogaert P, Azizieh R, Désir J, et al. Mutation of a potassium
channel-related gene in progressive myoclonic epilepsy. Ann Neurol
2007;61:579–586.
50. Van Bogaert P. KCTD7-related progressive myoclonus epilepsy.
Epileptic Disord 2016;18:115–119.
51. Bonten E, Van Der Spoel A, Fornerod M, Grosveld G, D’Azzo A.
Characterization of human lysosomal neuraminidase deﬁnes the
molecular basis of the metabolic storage disorder sialidosis. Genes
Dev 1996;10:3156–3169.
52. Franceschetti S, Canafoglia L. Sialidoses. Epileptic Disord 2016;18:
89–93.
53. Chan EM, Young EJ, Ianzano L, et al. Mutations in NHLRC1 cause
progressive myoclonus epilepsy. Nat Genet 2003;35:125–127.
54. Rawlings ND, Barrett AJ. Tripeptidyl-peptidase I is apparently the
CLN2 protein absent in classical late-infantile neuronal ceroid
lipofuscinosis. Biochim Biophys Acta 1999;1429:496–500.
55. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene
encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome.
Nat Genet 2001;29:66–69.
56. Mencacci NE, Rubio-Agusti I, Zdebik A, et al. A missense muta-
tion in KCTD17 causes autosomal dominant myoclonus-dystonia.
Am J Hum Genet 2015;96:938–947.
57. Savitsky K, Bar-shira A, Gilad S, et al. A Single Ataxia Telangiecta-
sia Gene with a Product Similar to PI-3 Kinase. Science 1995;268:
1749–1753.
58. Pearson TS. More Than Ataxia: Hyperkinetic Movement Disorders
in Childhood Autosomal Recessive Ataxia Syndromes. Tremor
Other Hyperkinet Mov (N Y) 2016;6:368.
59. Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG
repeat in hereditary dentatorubral-pallidoluysian atrophy
(DRPLA). Nat Genet 1994;6:9–13.
60. Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 dis-
ease gene: homology to mediators of cholesterol homeostasis. Sci-
ence 1997;277:228–231.
61. Anheim M, Lagha-Boukbiza O, Fleury-Lesaunier M-C, et al. Het-
erogeneity and frequency of movement disorders in juvenile and
adult-onset Niemann-Pick C disease. J Neurol 2014;261:174–179.
62. Chen DH, Brkanac Z, Verlinde CLMJ, et al. Missense mutations in
the regulatory domain of PKC gamma: a new mechanism for domi-
nant nonepisodic cerebellar ataxia. Am J Hum Genet 2003;72:
839–849.
63. Miura S, Nakagawara H, Kaida H, et al. Expansion of the pheno-
typic spectrum of SCA14 caused by the Gly128Asp mutation in
PRKCG. Clin Neurol Neurosurg 2009;111:211–215.
64. Stamelou M, Charlesworth G, Cordivari C, et al. The phenotypic
spectrum of DYT24 due to ANO3 mutations. Mov Disord 2014;
29:928–934.
65. Chen YZ, Matsushita MM, Robertson P, et al. Autosomal domi-
nant familial dyskinesia and facial myokymia: single exome
sequencing identiﬁes a mutation in adenylyl cyclase 5. Arch Neurol
2012;69:630–635.
66. Tunc S, Brüggemann N, Baaske MK, et al. Facial twitches in
ADCY5-associated disease — Myokymia or myoclonus? An elec-
tromyography study. Parkinsonism Relat Disord 2017;40:73–75.
67. Anon. The Huntington’s Disease Collaborative Researches Group.
A novel gene containing a trinucleotide repeat that is expanded and
unstable on Huntington’s disease chromosom. Cell 1993;72:
971–983.
68. Rossi Sebastiano D, Soliveri P, Panzica F, et al. Cortical myoclonus
in childhood and juvenile onset Huntington’s disease. Parkinsonism
Relat Disord 2012;18:794–797.
69. Breedveld GJ, van Dongen JWF, Danesino C, et al. Mutations in
TITF-1 are associated with benign hereditary chorea. Hum Mol
Genet 2002;11:971–979.
70. Duis J, Dean S, Applegate C, et al. KIF5A mutations cause an
infantile onset phenotype including severe myoclonus with evidence
of mitochondrial dysfunction. Ann Neurol 2016;80:633–637.
71. Rydzanicz M, Jagła M, Kosinska J, et al. KIF5A de novo mutation
associated with myoclonic seizures and neonatal onset progressive
leukoencephalopathy. Clin Genet 2017;91:769–773.
72. Nascimento FA, Canafoglia L, Aljaafari D, et al. Progressive myoc-
lonus epilepsy associated with SACS gene mutations. Neurol Genet
2016;2:e83.
73. Tsuji S, Choudary P V., Martin BM, et al. A Mutation in the
Human Glucocerebrosidase Gene in Neuronopathic Gaucher’s Dis-
ease. N Engl J Med 1987;316:570–575.
74. Park JK, Orvisky E, Tayebi N, et al. Myoclonic epilepsy in
Gaucher disease: Genotype-phenotype insights from a rare patient
subgroup. Pediatr Res 2003;53:387–395.
75. Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a
missense mutation in the amyloid precursor protein gene with
familial Alzheimer’s disease. Nature 1991;349:704–706.
76. Zhou J, Tawk M, Tiziano FD, et al. Spinal Muscular Atrophy
Associated with Progressive Myoclonic Epilepsy Is Caused by
Mutations in ASAH1. Am J Hum Genet 2012 91:5–14.
Movement Disorders, 2019 11
N O M E N C L A T U R E O F G E N E T I C M Y O C L O N U S S Y N D R O M E S
77. Poirier K, Hubert L, Viot G, et al. CSNK2B splice site mutations in
patients cause intellectual disability with or without myoclonic epi-
lepsy. Hum Mutat 2017:932–941.
78. Takano T, Shimmoto M, Fukuhara Y, et al. Galactosialidosis: clini-
cal and molecular analysis of 19 Japanese patients. Brain Dysfunct
1991;4:271–280.
79. Annunziata I and d’Azzo A. Galactosialidosis: historic aspects and
overview of investigated and emerging treatment options. Expert
Opin Orphan Drugs 2017;5:131–141.
80. Elo JM, Yadavalli SS, Euro L, et al. Mitochondrial phenylalanyl-
tRNA synthetase mutations underlie fatal infantile Alpers encepha-
lopathy. Hum Mol Genet 2012;21:4521–4529.
81. Goldgaber D, Goldfarb LG, Brown P, et al. Mutations in familial
Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker’s
syndrome. Exp Neurol 1989;106:204–206.
82. Manix M, Kalakoti P, Henry M, et al. Creutzfeldt-Jakob disease:
updated diagnostic criteria, treatment algorithm, and the utility of
brain biopsy. Neurosurg Focus 2015;39:E2.
83. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing
missense mutations in early-onset familial Alzheimer’s disease.
Nature 1995;375:754–760.
84. Ryan NS, Nicholas JM, Weston PSJ, et al. Clinical phenotype and
genetic associations in autosomal dominant familial Alzheimer’s
disease: a case series. Lancet Neurol 2016;15:1326–1335.
85. Trivier E, De Cesare D, Jacquot S, et al. Mutations in the kinase Rsk-2
associated with Cofﬁn-Lowry syndrome.Nature 1996;384:567–570.
86. Van Egmond ME, Elting JWJ, Kuiper A, et al. Myoclonus in
childhood-onset neurogenetic disorders: The importance of early iden-
tiﬁcation and treatment. Eur J Paediatr Neurol 2015;19:726–729.
87. Mullen SA, Marini C, Suls A, et al. Glucose Transporter 1 Deﬁ-
ciency as a Treatable Cause of Myoclonic Astatic Epilepsy. Arch
Neurol 2011;68:1152.
88. Koch H and Weber YG. The glucose transporter type 1 (Glut1)
syndromes. Epilepsy Behav 2018;1:4–7.
89. Vissers LELM, de Ligt J, Gilissen C, et al. A de novo paradigm for
mental retardation. Nat Genet 2010;42:1109–1112.
90. Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause
Angelman syndrome. Nat Genet 1997;15:70–73.
91. Pollack SF, Grocott OR, Parkin KA, Larson AM, Thibert RL. Myoc-
lonus in Angelman syndrome. Epilepsy Behav 2018;82:170–174.
92. Kotzot D, Schmitt S, Bernasconi F, et al. Uniparental disomy 7 in
Silver-Russell syndrome and primordial growth retardation. Hum
Mol Genet 1995;4:583–587.
93. Zutt R, Elting JW, van der Hoeven JH, Lange F, Tijssen MAJ. Myoc-
lonus subtypes in tertiary referral center. Cortical myoclonus and
functional jerks are common. Clin Neurophysiol 2017;128:253–259.
94. Van der Veen S, Zutt R, Becker CE, Elting JWJ, De Koning TJ,
Tijssen MAJ. Progressive Myoclonus Ataxia Time for a New Deﬁ-
nition? MovDisord 2018;33:1281–1286.
95. Franceschetti S, Michelucci R, Canafoglia L, et al. Progressive myo-
clonic epilepsies Deﬁnitive and still undetermined causes. Neurol-
ogy 2014;82:405–411.
96. Ishiura H, Doi K, Mitsui J, et al. Expansions of intronic TTTCA
and TTTTA repeats in benign adult familial myoclonic epilepsy.
Nat Genet 2018;50:581–590.
97. Van Rootselaar AF, Van Der Salm SMA, Bour LJ, et al. Decreased
cortical inhibition and yet cerebellar pathology in “familial cortical
myoclonic tremor with epilepsy.”Mov Disord 2007;22:2378–2385.
98. Ganos C, Kassavetis P, Erro R, Edwards MJ, Rothwell J and
Bhatia KP. The role of the cerebellum in the pathogenesis of corti-
cal myoclonus. Mov Disord 2014;29:437–443.
99. Bhat S and Ganesh S. New discoveries in progressive myoclonus
epilepsies: a clinical outlook. Expert Rev Neurother 2018;18:
649–667.
100. Corbett MA, Schwake M, Bahlo M, et al. A mutation in the Golgi
Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy
with early ataxia. Am J Hum Genet 2011;88:657–663.
101. Nardocci N, Zorzi G, Barzaghi C, et al. Myoclonus-dystonia syn-
drome: clinical presentation, disease course, and genetic features in
11 families. Mov Disord 2008;23:28–34.
102. Roze E, Lang AE, Vidailhet M. Myoclonus-dystonia: classiﬁcation,
phenomenology, pathogenesis, and treatment. Curr Opin Neurol
2018;31:484–490.
103. Eberhardt O, Topka H. Myoclonic disorders. Brain Sci 2017;7(8):
pii: E103.
104. Dijk JM, Tijssen MAJ. Management of patients with myoclonus:
Available therapies and the need for an evidence-based approach.
Lancet Neurol 2010;9:1028–1036.
105. Apartis E and Vercueil L. To jerk or not to jerk: A clinical patho-
physiology of myoclonus. Rev Neurol (Paris) 2016;172:465–476.
106. Boissé Lomax L, Bayly MA, Hjalgrim H, et al. “North Sea” pro-
gressive myoclonus epilepsy: phenotype of subjects with GOSR2
mutation. Brain 2013;136:1146–1154.
107. van Egmond ME, Verschuuren-Bemelmans CC, Nibbeling EA, et al.
Ramsay hunt syndrome: Clinical characterization of progressive
myoclonus ataxia caused by GOSR2 mutation. Mov Disord 2014;
29:139–143.
108. Zutt R, Gelauff JM, Smit M, Zijl JC Van, Stone J and
Tijssen MAJ. The presence of depression and anxiety do not distin-
guish between functional jerks and cortical myoclonus. Parkinson-
ism Relat Disord 2017;45:90–93.
109. Skorvanek M, Rosenberger J, Minar M, et al. Relationship between
the non-motor items of the MDS-UPDRS and Quality of Life in
patients with Parkinson’s disease. J Neurol Sci 2015;353:87–91.
110. Lill CM, Mashychev A, Hartmann C, et al. Launching the move-
ment disorders society genetic mutation database (MDSGene).
Mov. Disord 2016;31:607–609.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
12 Movement Disorders, 2019
V A N D E R V E E N E T A L
